Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations

Zimmerli, 2004, Prosthetic-joint infections, N Engl J Med, 351, 1645, 10.1056/NEJMra040181 Becker, 2014, Coagulase-negative staphylococci, Clin Microbiol Rev, 27, 870, 10.1128/CMR.00109-13 Widerström, 2012, Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus, Eur J Clin Microbiol Infect Dis, 31, 7, 10.1007/s10096-011-1270-6 Patel, 2005, Biofilms and antimicrobial resistance, Clin Orthop Relat Res, 41, 10.1097/01.blo.0000175714.68624.74 Donlan, 2002, Biofilms: survival mechanisms of clinically relevant microorganisms, Clin Microbiol Rev, 15, 167, 10.1128/CMR.15.2.167-193.2002 Trampuz, 2006, Infections associated with orthopedic implants, Curr Opin Infect Dis, 19, 349, 10.1097/01.qco.0000235161.85925.e8 Costerton, 2005, Biofilm theory can guide the treatment of device-related orthopaedic infections, Clin Orthop Relat Res, 7, 10.1097/00003086-200508000-00003 Crowe, 2003, Revision total hip arthroplasty: hospital cost and reimbursement analysis, Clin Orthop Relat Res, 175, 10.1097/01.blo.0000072469.32680.b6 Zimmerli, 1998, Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group, JAMA, 279, 1537, 10.1001/jama.279.19.1537 Campbell, 2001, Structural mechanism for rifampicin inhibition of bacterial RNA polymerase, Cell, 104, 901, 10.1016/S0092-8674(01)00286-0 Adekambi, 2009, The rpoB gene as a tool for clinical microbiologists, Trends Microbiol, 17, 37, 10.1016/j.tim.2008.09.008 Tupin, 2010, Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns, Int J Antimicrob Agents, 35, 519, 10.1016/j.ijantimicag.2009.12.017 O'Neill, 2006, Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence, Antimicrob Agents Chemother, 50, 298, 10.1128/AAC.50.1.298-309.2006 Clinical and Laboratory Standards Institute, 2017 Brinkman, 2015, Causes and implications of the disappearance of rifampin resistance in a rat model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis, Antimicrob Agents Chemother, 59, 4481, 10.1128/AAC.05078-14 Lee, 2016, Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa, Sci Rep, 6, 25543, 10.1038/srep25543 Furustrand Tafin, 2013, In vitro emergence of rifampicin resistance in Propionibacterium acnes and molecular characterization of mutations in the rpoB gene, J Antimicrob Chemother, 68, 523, 10.1093/jac/dks428 Aubry-Damon, 1998, Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus, Antimicrob Agents Chemother, 42, 2590, 10.1128/AAC.42.10.2590 Lee, 2016, Functional analysis of the first complete genome sequence of a multidrug resistant sequence type 2 Staphylococcus epidermidis, Microb Genom, 2 Bankevich, 2012, SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing, J Comput Biol, 19, 455, 10.1089/cmb.2012.0021 Salipante, 2015, Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology, J Clin Microbiol, 53, 1072, 10.1128/JCM.03385-14 Gaupp, 2015, Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype, Antimicrob Agents Chemother, 59, 4226, 10.1128/AAC.00160-15 Wichelhaus, 2002, Biological cost of rifampin resistance from the perspective of Staphylococcus aureus, Antimicrob Agents Chemother, 46, 3381, 10.1128/AAC.46.11.3381-3385.2002 Floss, 2005, Rifamycin—mode of action, resistance, and biosynthesis, Chem Rev, 105, 621, 10.1021/cr030112j Hellmark, 2009, Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene, Clin Microbiol Infect, 15, 238, 10.1111/j.1469-0691.2008.02663.x Cui, 2010, An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus, Antimicrob Agents Chemother, 54, 5222, 10.1128/AAC.00437-10 Katayama, 2016, Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus phenotype of strain Mu50 in vancomycin-susceptible S. aureus, Antimicrob Agents Chemother, 60, 3730, 10.1128/AAC.00420-16 Matsuo, 2011, Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3, Antimicrob Agents Chemother, 55, 4188, 10.1128/AAC.00398-11 Wichelhaus, 1999, Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 43, 2813, 10.1128/AAC.43.11.2813 Andersson, 1999, The biological cost of antibiotic resistance, Curr Opin Microbiol, 2, 489, 10.1016/S1369-5274(99)00005-3 Björkman, 2000, The cost of antibiotic resistance from a bacterial perspective, Drug Resist Updat, 3, 237, 10.1054/drup.2000.0147 Levin, 1997, The population genetics of antibiotic resistance, Clin Infect Dis, 24, S9, 10.1093/clinids/24.Supplement_1.S9 Gagneux, 2006, The competitive cost of antibiotic resistance in Mycobacterium tuberculosis, Science, 312, 1944, 10.1126/science.1124410 Böttger, 1998, Fitness of antibiotic-resistant microorganisms and compensatory mutations, Nat Med, 4, 1343, 10.1038/3906 Vergidis, 2015, Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis, J Infect, 70, 609, 10.1016/j.jinf.2014.12.016 Aiba, 2013, Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 57, 4861, 10.1128/AAC.00720-13 Enne, 2004, Rifampicin resistance and its fitness cost in Enterococcus faecium, J Antimicrob Chemother, 53, 203, 10.1093/jac/dkh044